ClinicalTrials.gg
CompletedNCT05470894Updated Mar 24, 2025

Liver Injury After COVID-19 Vaccination

An observational study in Subjects After COVID-19 Vaccination, sponsored by Humanity & Health Medical Group Limited. Completed at 3 sites in 2 countries. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Humanity & Health Medical Group Limited · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
379
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in COVID-19 with a site in Japan — 10 open to participants now, 11 under way, 8 of them phase 3. COVID-19 · Japan.

Enrollment
12th of 15
379 · median 3,346
Started
2022
with 12 others
Observational
15 of 75
none open now
Registered
53rd of 75
by date

Among the 75 studies in COVID-19 with a site in Japan, this one is the 12th largest by enrollment of the 15 observational ones that give a count, is one of 13 that started in 2022, is one of 15 observational ones, and was the 53rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

10 of the 75 studies in COVID-19 with a site in Japan are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 5 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in COVID-19 with a site in Japan, or all of them as a file.
02

Study summary

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is still raging across the world and vaccination is expected to lead us out of this pandemic. Although the efficacy of these vaccines is beyond doubt, safety still remains a concern. Liver injury, such as autoimmune hepatitis (AIH), has been reported after COVID-19 vaccination. The aim of this prospective study is to investigate the spectrum and profile of liver injury after COVID-19 vaccination in Asia-Pacific region and to explore the potential risk factors for the development of liver injury.

03

Conditions studied

  • Subjects After COVID-19 Vaccination

Browse trials for

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects after COVID-19 vaccination

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have received at least one dose of approved COVID-19 vaccine;
  • Volunteer to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • No valid consent.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
379 participants (actual)
Patient registry
No

Groups and cohorts

  • COVID-19 Vaccination Group

    Subjects who have received at lease one dose of approved COVID-19 vaccine

    Biological: Approved COVID-19 vaccine

Interventions

  • BiologicalApproved COVID-19 vaccine

    Vaccination for COVI9-19

06

What researchers measure

Primary outcomes

  1. Number of subjects with liver injury after COVID-19 vaccination

    The COVID-19 vaccine-related liver injury (such as elevated liver enzymes, total bilirubin, etc.) was recorded and its spectrum and profile were evaluated.

    Time frame: Within 24 weeks after COVID-19 vaccination

07

Study locations

3 sites
  • Humanity & Health Medical Group Limited
    Hong Kong, Hong Kong
  • Nihon University School of Medicine
    Tokyo, Japan
  • Tokyo University
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Dec 2024, 27 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 27 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2022
First posted
Jul 22, 2022
StartActual
Sep 5, 2022
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05470894
Lead sponsor
Humanity & Health Medical Group Limited
Collaborators
Tokyo University, Nihon University School of Medicine
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Sep 5, 2022
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Mar 24, 2025

Study contacts

George Lau, MD
principal investigator · Humanity & Health Medical Group
Masao Omata, MD, PhD
principal investigator · Tokyo University
Tatsuo Kanda, MD, PhD
principal investigator · Nihon University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion